Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post Panels, Telaprevir And Boceprevir Now Face FDA's Risk Management Review

Executive Summary

Coming out of FDA’s Antiviral Drugs Advisory Committee reviews with ringing endorsement for both Vertex Pharmaceuticals’ telaprevir and Merck’s boceprevir, the attention now shifts to risk management for the anemia associated with both protease inhibitors for hepatitis C and for rash associated with telaprevir.
Advertisement

Related Content

Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
Vertex's Telaprevir Slides By Advisory Committee, But Panelists Want Limits On Some Patients
Advisory Panel Backs Broad Boceprevir Label, But With Discussion Of Drug's Data Limitations

Topics

Advertisement
UsernamePublicRestriction

Register

PS053362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel